CRISPR obtained approval for Casgevy back in 2023, but the rollout has been slow. In 2025, the company incurred a loss of more than $580 million. Its cash position, however, remains strong.

Investors have bought into the promise of CRISPR technology for years. The ability to target and edit genes to treat cancer ...

Casgevy is starting to build some serious sales momentum. CRISPR Therapeutics also has a deep pipeline and healthy funding. The stock requires patience, but there is a visible path to a bright future.

A sales partner offered a ray of hope that this company couldn't for itself.

These biotech companies have catalysts ahead.